explore -WSS

explore

author：knowledge 2025-09-29 21:27:13 - browse：2

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： How to pay for weight loss drugs and save Medicare

leisure time

focus

WSS

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

CDC director unscathed in first congressional testimony

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

What AstraZeneca

With clinical trial data readouts, here's how to spot spin

Organ aging and disease risk measured by new blood test

leisure time

explore

focus

Bright Health sells Medicare Advantage business to Molina

Snowpack in the West is melting rapidly. Where will all that extra water go?

ChatGPT in medicine: STAT answers readers' burning questions

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Hepatitis C has a cure — but many Americans still lack access to it

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Activists slam private health insurers over coverage restrictions

Doctors increasingly discourage vaping amid mounting health concerns

entertainment

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Takeda, Janssen join wearable maker to measure scratching

FDA investigates CAR

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Poland's lawmakers approve a divisive law on Russian influence

Trump team launching legal defense fund to help pay legal bills

knowledge

leisure time

focus

hotspot